Alkermes’ alixorexton improves narcolepsy type 2 symptoms as Phase 3 risk comes into focus
Discover how Alkermes’ alixorexton could reshape narcolepsy type 2 treatment as Phase 3 tests its efficacy, dosing and long-term safety.
Pharma & Biotech